Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2012, Article ID 623465, 9 pages
http://dx.doi.org/10.1155/2012/623465
Review Article

Molecular Signature in HCV-Positive Lymphomas

1Unit of Clinical and Experimental Pharmacology, IRCCS, Centro di Riferimento Oncologico, National Cancer Institute, 33081 Aviano, Pordenone, Italy
2Clinical and Experimental Pharmacology, Centro di Riferimento Oncologico, IRCCS, 33081 Aviano, Pordenone, Italy

Received 24 April 2012; Revised 29 June 2012; Accepted 3 July 2012

Academic Editor: Domenico Sansonno

Copyright © 2012 Valli De Re et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Sansonno, A. Carbone, V. De Re, and F. Dammacco, “Hepatitis C virus infection, cryoglobulinaemia, and beyond,” Rheumatology, vol. 46, no. 4, pp. 572–578, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. S. De Sanjose, Y. Benavente, C. M. Vajdic et al., “Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium,” Clinical Gastroenterology and Hepatology, vol. 6, no. 4, pp. 451–458, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Talamini, M. Montella, M. Crovatto et al., “Non-Hodgkin's lymphoma and hepatitis C virus: a case-control study from northern and southern Italy,” International Journal of Cancer, vol. 110, no. 3, pp. 380–385, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Mariano, G. Scalia Tomba, M. E. Tosti, E. Spada, and A. Mele, “Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy,” Scandinavian Journal of Infectious Diseases, vol. 41, no. 9, pp. 689–699, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. Y. Kasama, S. Sekiguchi, M. Saito et al., “Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo,” Blood, vol. 116, no. 23, pp. 4926–4933, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Sansonno, F. A. Tucci, G. Lauletta et al., “Hepatitis C virus productive infection in mononuclear cells from patients with cryoglobulinaemia,” Clinical and Experimental Immunology, vol. 147, no. 2, pp. 241–248, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. M. H. V. Sung, S. Shimodaira, A. L. Doughty et al., “Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection,” Journal of Virology, vol. 77, no. 3, pp. 2134–2146, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. Z. Chen, Y. Zhu, Y. Ren et al., “Hepatitis C virus protects human B lymphocytes from fas-mediated apoptosis via E2-CD81 engagement,” PLoS ONE, vol. 6, no. 4, Article ID e18933, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. V. De Re, S. De Vita, A. Marzotto et al., “Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus—associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factorn—producing cells that occur mainly in type II cryoglobulinemia,” Blood, vol. 96, no. 10, pp. 3578–3584, 2000. View at Google Scholar · View at Scopus
  10. V. De Re, S. De Vita, A. Marzotto et al., “Pre-malignant and malignant lymphoproliferations in an HCV-infected type II mixed cryoglobulinemic patient are sequential phases of an antigen-driven pathological process,” International Journal of Cancer, vol. 87, no. 2, pp. 211–216, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Dammacco, F. A. Tucci, G. Lauletta et al., “Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study,” Blood, vol. 116, no. 3, pp. 343–353, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. S. K. Hartridge-Lambert, E. M. Stein, A. J. Markowitz, and C. S. Portlock, “Hepatitis C and non-hodgkin lymphoma: the clinical perspective,” Hepatology, vol. 55, no. 2, pp. 634–641, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Kawamura, K. Ikeda, Y. Arase et al., “Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C,” American Journal of Medicine, vol. 120, no. 12, pp. 1034–1041, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Mazzaro, G. Monti, F. Saccardo et al., “Efficacy and safety of Peginterferon alfa-2b plus Ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study,” Clinical and Experimental Rheumatology, vol. 29, no. 6, pp. 933–941, 2011. View at Google Scholar · View at Scopus
  15. D. Vallisa, P. Bernuzzi, L. Arcaini et al., “Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience,” Journal of Clinical Oncology, vol. 23, no. 3, pp. 468–473, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Sansonno, V. De Re, G. Lauletta, F. A. Tucci, M. Boiocchi, and F. Dammacco, “Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon α with an anti-CD20,” Blood, vol. 101, no. 10, pp. 3818–3826, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Saadoun, F. Suarez, F. Lefrere et al., “Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?” Blood, vol. 105, no. 1, pp. 74–76, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Libra, J. Polesel, A. E. Russo et al., “Extrahepatic disorders of HCV infection: a distinct entity of B-cell neoplasia?” International Journal of Oncology, vol. 36, no. 6, pp. 1331–1340, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Ruiz-Ballesteros, M. Mollejo, A. Rodriguez et al., “Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis,” Blood, vol. 106, no. 5, pp. 1831–1838, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. A. J. Arribas, Y. Campos-Martín, C. Gómez-Abad et al., “Nodal marginal zone lymphoma: gene expression and miRNA profiling identify diagnostic markers and potential therapeutic targets,” Blood, vol. 119, no. 3, pp. e9–e21, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Rossi, S. Deaglio, D. Dominguez-Sola et al., “Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma,” Blood, vol. 118, no. 18, pp. 4930–4934, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. Q. Yan, Y. Huang, A. James Watkins et al., “BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas,” Haematologica, vol. 97, no. 4, pp. 595–598, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Kikuma, J. Watanabe, Y. Oshiro et al., “Etiological factors in primary hepatic B-cell lymphoma,” Virchows Archiv, vol. 460, no. 4, pp. 379–387, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. V. De Re, D. Sansonno, M. P. Simula et al., “HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferations,” Leukemia, vol. 20, no. 6, pp. 1145–1154, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. D. A. Landau, D. Saadoun, L. H. Calabrese, and P. Cacoub, “The pathophysiology of HCV induced B-cell clonal disorders,” Autoimmunity Reviews, vol. 6, no. 8, pp. 581–587, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Sansonno, S. De Vita, V. Cornacchiulo, A. Carbone, M. Boiocchi, and F. Dammacco, “Detection and distribution of hepatitis C virus-related proteins in lymph nodes of patients with type II mixed cryoglobulinemia and neoplastic or non-neoplastic lymphoproliferation,” Blood, vol. 88, no. 12, pp. 4638–4645, 1996. View at Google Scholar · View at Scopus
  27. V. De Re, A. Pavan, S. Sansonno, D. Sansonno, and V. Racanelli, “Clonal CD27+ CD19+ B cell expansion through inhibition of FCγIIR in HCV+ cryoglobulinemic patients: a model,” Annals of the New York Academy of Sciences, vol. 1173, pp. 326–333, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Sansonno, F. A. Tucci, B. Ghebrehiwet et al., “Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage,” Journal of Immunology, vol. 183, no. 9, pp. 6013–6020, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Bataille, G. Kaplanski, J. Boucraut et al., “Membranoproliferative glomerulonephritis and mixed cryoglobulinemia after hepatitis C virus infection secondary to glomerular NS3 viral antigen deposits,” American Journal of Nephrology, vol. 35, no. 2, pp. 134–140, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Cao, Y. Zhang, S. Wang, and W. Zou, “Detection of the hepatitis C virus antigen in kidney tissue from infected patients with various glomerulonephritis,” Nephrology Dialysis Transplantation, vol. 24, no. 9, pp. 2745–2751, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. E. D. Charles, C. Brunetti, S. Marukian et al., “Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset,” Blood, vol. 117, no. 20, pp. 5425–5437, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. V. De Re, S. De Vita, D. Sansonno et al., “Type II mixed cryoglobulinaemia as an oligo rather than a mono B-cell disorder: evidence from GeneScan and MALDI-TOF analyses,” Rheumatology, vol. 45, no. 6, pp. 685–693, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. V. Racanelli, C. Brunetti, V. de Re et al., “Antibody vh repertoire differences between resolving and chronically evolving hepatitis C virus infections,” PLoS ONE, vol. 6, no. 9, Article ID e25606, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. C. Wu, D. Kipling, and D. K. Dunn-Walters, “The relationship between CD27 negative and positive B cell populations in human peripheral blood,” Frontiers in Immunology, vol. 2, article 81, 2011. View at Google Scholar
  35. B. Terrier, F. Joly, T. Vazquez et al., “Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity,” Journal of Immunology, vol. 187, no. 12, pp. 6550–6563, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. I. Sanz, C. Wei, F. E. H. Lee, and J. Anolik, “Phenotypic and functional heterogeneity of human memory B cells,” Seminars in Immunology, vol. 20, no. 1, pp. 67–82, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Malaspina, S. Moir, J. Ho et al., “Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 7, pp. 2262–2267, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Moir, J. Ho, A. Malaspina et al., “Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals,” Journal of Experimental Medicine, vol. 205, no. 8, pp. 1797–1805, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Wei, J. Anolik, A. Cappione et al., “A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus,” Journal of Immunology, vol. 178, no. 10, pp. 6624–6633, 2007. View at Google Scholar · View at Scopus
  40. G. E. Weiss, P. D. Crompton, S. Li et al., “Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area,” Journal of Immunology, vol. 183, no. 3, pp. 2176–2182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. R. A. Moura, P. Weinmann, P. A. Pereira et al., “Alterations on peripheral blood B-cell subpopulations in very early arthritis patients,” Rheumatology, vol. 49, no. 6, pp. 1082–1092, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Silva, D. M. Andrews, A. G. Brooks, M. J. Smyth, and Y. Hayakawa, “Application of CD27 as a marker for distinguishing human NK cell subsets,” International Immunology, vol. 20, no. 4, pp. 625–630, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. L. E. Holz, J. C. Yoon, S. Raghuraman et al., “B-cell homeostasis in chronic hepatitis C virus-related mixed cryoglobulinemia is maintained through naive B-cell apoptosis,” Hepatology, vol. 10, pp. 4–5, 2012. View at Google Scholar
  44. M. Visentini, M. Cagliuso, V. Conti et al., “Clonal B cells of HCV-associated mixed cryoglobulinemia patients contain exhausted marginal zone-like and CD21low cells overexpressing Stra13,” European Journal of Immunology, vol. 42, no. 6, pp. 1468–1476, 2012. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Visentini, V. Conti, M. Cagliuso et al., “Persistence of a large population of exhausted monoclonal B cells in mixed cryoglobuliemia after the eradication of hepatitis C virus infection,” Journal of Clinical Immunology, vol. 32, no. 4, pp. 729–735, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Carbonari, E. Caprini, T. Tedesco et al., “Hepatitis C virus drives the unconstrained monoclonal expansion of V H1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis,” Journal of Immunology, vol. 174, no. 10, pp. 6532–6539, 2005. View at Google Scholar · View at Scopus
  47. L. Goldberg-Bittman, Y. Kitay-Cohen, M. D. Fejgin, R. Hadary, M. Quitt, and A. Amiel, “TERC telomerase subunit gene copy number in different disease stages of non-Hodgkin lymphoma and in hepatitis C,” Cancer Investigation, vol. 28, no. 2, pp. 181–185, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. H. Farawela, M. Khorshied, I. Shaheen et al., “The association between hepatitis C virus infection, genetic polymorphisms of oxidative stress genes and B-cell non-Hodgkin's lymphoma risk in Egypt,” Infection, Genetics and Evolution, vol. 12, no. 6, pp. 1189–1194, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Zibellini, D. Capello, F. Forconi et al., “Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma,” Haematologica, vol. 95, no. 10, pp. 1792–1796, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Libra, A. Gloghini, G. Malaponte et al., “Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas,” Journal of Hepatology, vol. 49, no. 2, pp. 170–174, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Fabris, L. Quartuccio, S. Sacco et al., “B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection,” Rheumatology, vol. 46, no. 1, pp. 37–43, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. G. Geri, B. Terrier, O. Semoun et al., “Surrogate markers of B cell non-Hodgkin's lymphoma in patients with hepatitis C virus-related cryoglobulinaemia vasculitis,” Annals of the Rheumatic Diseases, vol. 69, no. 12, pp. 2177–2180, 2010. View at Publisher · View at Google Scholar · View at Scopus
  53. F. Mackay, P. Schneider, P. Rennert, and J. Browning, “BAFF and APRIL: a tutorial on B cell survival,” Annual Review of Immunology, vol. 21, pp. 231–264, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Batten, J. Groom, T. G. Cachero et al., “BAFF mediates survival of peripheral immature B lymphocytes,” Journal of Experimental Medicine, vol. 192, no. 10, pp. 1453–1465, 2000. View at Publisher · View at Google Scholar · View at Scopus
  55. I. Castro, J. A. Wright, B. Damdinsuren et al., “B cell receptor-mediated sustained c-Rel activation facilitates late transitional B cell survival through control of B cell activating factor receptor and NF-κB2,” Journal of Immunology, vol. 182, no. 12, pp. 7729–7737, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Basak, V. F.-S. Shih, and A. Hoffmann, “Generation and activation of multiple dimeric transcription factors within the NF-κB signaling system,” Molecular and Cellular Biology, vol. 28, no. 10, pp. 3139–3150, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. H. C. Liou and C. Y. Hsia, “Distinctions between c-Rel and other NF-κB proteins in immunity and disease,” BioEssays, vol. 25, no. 8, pp. 767–780, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. R. Tussiwand, M. Rauch, L. A. Flück, and A. G. Rolink, “BAFF-R expression correlates with positive selection of immature B cells,” European Journal of Immunology, vol. 42, no. 1, pp. 206–216, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. J. E. Crowley, J. E. Stadanlick, J. C. Cambier, and M. P. Cancro, “Fc{gamma}RIIB signals inhibit BLyS signaling and BCR-mediated BLyS receptor up-regulation,” Blood, vol. 113, no. 7, pp. 1464–1473, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. W. N. Khan, “B cell receptor and BAFF receptor signaling regulation of B cell homeostasis,” Journal of Immunology, vol. 183, no. 6, pp. 3561–3567, 2009. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Kreuzaler, M. Rauch, U. Salzer et al., “Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors,” Journal of Immunology, vol. 188, no. 1, pp. 497–503, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. A. M. Jacobi, W. Huang, T. Wang et al., “Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study,” Arthritis and Rheumatism, vol. 62, no. 1, pp. 201–210, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. J. L. Scholz and M. P. Cancro, “Resolve, revise, and relax: the 3 Rs of B cell repertoire adjustment,” Immunology Letters, vol. 143, no. 1, pp. 2–8, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. J. F. Treml, Y. Hao, J. E. Stadanlick, and M. P. Cancro, “The BLyS family: toward a molecular understanding of B cell homeostasis,” Cell Biochemistry and Biophysics, vol. 53, no. 1, pp. 1–16, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. M. P. Cancro, D. P. D'Cruz, and M. A. Khamashta, “The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus,” The Journal of Clinical Investigation, vol. 119, no. 5, pp. 1066–1073, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. A. L. Shaffer, R. M. Young, and L. M. Staudt, “Pathogenesis of human B cell lymphomas,” Annual Review of Immunology, vol. 30, pp. 565–610, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. L. Chen, S. Monti, P. Juszczynski et al., “SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma,” Blood, vol. 111, no. 4, pp. 2230–2237, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. J. E. Stadanlick, M. Kaileh, F. G. Karnell et al., “Tonic B cell antigen receptor signals supply an NF-κB substrate for prosurvival BLyS signaling,” Nature Immunology, vol. 9, no. 12, pp. 1379–1387, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. F. Mackay, P. A. Silveira, and R. Brink, “B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling,” Current Opinion in Immunology, vol. 19, no. 3, pp. 327–336, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. K. Onda, K. Iijima, Y. U. Katagiri et al., “Differential effects of BAFF on B cell precursor acute lymphoblastic leukemia and Burkitt lymphoma,” International Journal of Hematology, vol. 91, no. 5, pp. 808–819, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. R. C. Rickert, J. Jellusova, and A. V. Miletic, “Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease,” Immunological Reviews, vol. 244, no. 1, pp. 115–133, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. L. Buonaguro, A. Petrizzo, M. Tornesello et al., “Immune signatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders,” Journal of Translational Medicine, vol. 8, article 18, 2010. View at Publisher · View at Google Scholar · View at Scopus
  73. J. M. Sugalski, B. Rodriguez, S. Moir, and D. D. Anthony, “Peripheral blood B cell subset skewing is associated with altered cell cycling and intrinsic resistance to apoptosis and reflects a state of immune activation in chronic hepatitis C Virus infection,” Journal of Immunology, vol. 185, no. 5, pp. 3019–3027, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. C. E. Osakwe, C. Bleotu, M. C. Chifiriuc et al., “TH1/TH2 cytokine levels as an indicator for disease progression in human immunodeficiency virus type 1 infection and response to antiretroviral therapy,” Roumanian Archives of Microbiology and Immunology, vol. 69, no. 1, pp. 24–34, 2010. View at Google Scholar · View at Scopus
  75. Z. Ren, G. Pang, R. Clancy et al., “Shift of the gastric T-cell response in gastric carcinoma,” Journal of Gastroenterology and Hepatology, vol. 16, no. 2, pp. 142–148, 2001. View at Publisher · View at Google Scholar · View at Scopus
  76. A. M. Atta, I. S. Oliveira, G. M. Sousa, R. Paraná, and M. L. Sousa Atta, “Serum cytokine profile in hepatitis C virus carriers presenting cryoglobulinaemia and non-organ-specific autoantibodies,” Microbial Pathogenesis, vol. 48, no. 2, pp. 53–56, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. W. S. Alexander, “Suppressors of cytokine signalling (SOCS) in the immune system,” Nature Reviews Immunology, vol. 2, no. 6, pp. 410–416, 2002. View at Google Scholar · View at Scopus
  78. Z. Q. Yao, L. Ni, Y. Zhang et al., “Differential regulation of t and b lymphocytes by pd-1 and SOCS-1 signaling in hepatitis C virus-associated non-hodgkin's lymphoma,” Immunological Investigations, vol. 40, no. 3, pp. 243–264, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. J. Moorman, Z. P. Dong, L. Ni, C. Zhang, T. Borthwick, and Z. Q. Yao, “Abnormal B-cell activation associated with TALL-1 over-expression and SOCS-1 suppression during chronic hepatitis C virus infection,” Immunology, vol. 128, no. 2, pp. 227–235, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Libra, D. Capello, A. Gloghini et al., “Analysis of aberrant somatic hypermutation (SHM) in non-Hodgkin's lymphomas of patients with chronic HCV infection,” Journal of Pathology, vol. 206, no. 1, pp. 87–91, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. V. De Re, L. Caggiari, G. Monti et al., “HLA DR-DQ combination associated with the increased risk of developing human HCV positive non-Hodgkin's lymphoma is related to the type II mixed cryoglobulinemia,” Tissue Antigens, vol. 75, no. 2, pp. 127–135, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. V. De Re, L. Caggiari, M. P. Simula et al., “Role of the HLA class II: HCV-related disorders,” Annals of the New York Academy of Sciences, vol. 1107, pp. 308–318, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. V. De Re, L. Caggiari, R. Talamini et al., “Hepatitis C virus-related hepatocellular carcinoma and B-cell lymphoma patients show a different profile of major histocompatibility complex class II alleles,” Human Immunology, vol. 65, no. 11, pp. 1397–1404, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. C. L. Jopling, M. Yi, A. M. Lancaster, S. M. Lemon, and P. Sarnow, “Molecular biology: modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA,” Science, vol. 309, no. 5740, pp. 1577–1581, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. J. Peveling-Oberhag, G. Crisman, A. Schmidt et al., “Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection,” Leukemia, vol. 26, no. 7, pp. 1654–1662, 2012. View at Publisher · View at Google Scholar · View at Scopus
  86. E. Ruiz-Ballesteros, M. Mollejo, M. Mateo, P. Algara, P. Martínez, and M. A. Piris, “MicroRNA losses in the frequently deleted region of 7q in SMZL,” Leukemia, vol. 21, no. 12, pp. 2547–2549, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. K. Machida, K. T. H. Cheng, V. M. H. Sung, A. M. Levine, S. Foung, and M. M. C. Lai, “Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6,” Journal of Virology, vol. 80, no. 2, pp. 866–874, 2006. View at Publisher · View at Google Scholar · View at Scopus
  88. G. Feldmann, H. D. Nischalke, J. Nattermann et al., “Induction of interleukin-6 by hepatitis C virus core protein in hepatitis C-associated mixed cryoglobulinemia and B-cell non-Hodgkin's lymphoma,” Clinical Cancer Research, vol. 12, no. 15, pp. 4491–4498, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. M. P. Purdue, Q. Lan, S. S. Wang et al., “A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma,” Carcinogenesis, vol. 30, no. 2, pp. 275–281, 2009. View at Publisher · View at Google Scholar · View at Scopus